medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 2

<< Back Next >>

Med Int Mex 2023; 39 (2)

Prognostic factors of mortality in patients with antiphospholipid syndrome in a cohort of Cuban patients

Pérez de Alejo-Rodríguez MM, Hernández-Negrín H, Barreto-Fui EE, Jiménez-Domínguez LJ

Language: Spanish
References: 43
Page: 251-265
PDF size: 253.89 Kb.


ABSTRACT

Objective: To determine the mortality prognostic factors in patients with antiphospholipid syndrome and to compare their survival according to the identified prognostic factors.
Materials and Methods: Observational analytical case-control study carried out in patients diagnosed with antiphospholipid syndrome treated at the Autoimmune Diseases clinic of the Arnaldo Milián Castro Hospital, Villa Clara, Cuba, from January 1990 to January 2015. They formed two groups: one with deceased patients and the other with living patients.
Results: Twenty patients were included in the group of deceased and 80 in the group of living patients. Multivariate analysis identified renal damage (p: 0.001; OR: 16.51; CI: 1.27-23.38), neurological damage (p: 0.030; OR: 5.24; CI: 1.27-23.38), pulmonary embolism (p: 0.033; OR: 9.76; CI: 1.20-79.28), false positivity for VDRL serology (p: 0.025; OR: 8.63; CI: 1.30 -57.14) and arterial thrombosis (p: 0.036; OR: 5.49; CI: 1.11-27.11).With the exception of arterial thromboses, the other factors determined a significantly lower mean survival in the patients who manifested them.
Conclusions: The early identification of these prognostic factors can facilitate the prediction of the outcome of this disease, which represents a decisive tool to prevent fatal complications and decide the most appropriate therapeutic approach, thus contributing to the improvement of the comprehensive care of patients with antiphospholipid syndrome.


REFERENCES

  1. Gavriș CM, Nedelcu LD, Pascu AM. Thrombotic risk inantiphospholipidic syndrome: From hypothesis to currentevidence (Review). Exp Ther Med 2021; 21 (3):287: doi:10.3892/etm.2021.9718.

  2. Uludag G , Onghanseng N, Tran AN, Hassan M, Sohail HalimM, Sepah YJ , et al. Current concepts in the diagnosis andmanagement of antiphospholipid syndrome and ocularmanifestations. J Ophthalmic Inflamm Infect 2021; 11 (1):11. doi: 10.1186/s12348-021-00240-8.

  3. C-HW HJ, Jiang N, Li J, Wu CY, Wang Q, Meng-Tao L, et al.Clinical characteristics and prognosis of patients with isolatedthrombotic vs. obstetric antiphospholipid syndrome:a prospective cohort study. Arthritis Res Ther 2021; 23 (1):138. doi: 10.1186/s13075-021-02515-w.

  4. Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of antiphospholipid syndrome inthe general population. Curr Rheumatol Rep 2022; 23(12):85. doi: 10.1007/s11926-021-01038-2.

  5. Reyes-Llerena GA, Guibert-Toledano M, Penedo-CoelloA, Pérez Rodríguez, A BDR, et al. Community based studyto estimate prevalence and burden of illness rheumaticdiseases in Cuba. A COPCORD study. J Clin Rheumatol2009; 15 (2): 51-5. doi: 10.1097/RHU.0b013e31819b61cb.

  6. Reyes-Llerena GA, Álvarez-Villanueva RR, Vasallo-Prieto R.Síndrome de anticuerpos antifosfolípidos en Obstetricia enuna serie de casos en Cuba. Rev Cubana Obstet Ginecol2016; 42 (3).

  7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL,Cervera R, et al. International consensus statement on anupdate of the classification criteria for definite antiphospholipidsyndrome (APS). J Thromb Haemost 2006; 4 (2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.

  8. Lazcano-Ponce ES-ME, Hernández-Avila M. Estudios epidemiológicosde casos y controles. Fundamento teórico, variantesy aplicaciones. Salud Pública Méx 2001; 43 (2): 135-50.

  9. Girón-González JA, García del Río E, Rodríguez C, Rodríguez-Martorell J, Serrano A. Antiphospholipid syndrome andasymptomatic carriers of antiphospholipid antibody:prospective analysis of 404 individuals. J Rheumatol 2004;31 (8): 1560-7.

  10. Guibert-Toledano ZM. Actividad lúpica y daño acumuladoen un cohorte de pacientes cubanos con Lupus eritematososistémico. Trabajo científico para optar al grado científicode Doctor en Ciencias Médicas. La Habana; 2009.

  11. Estévez del Toro MH. Indicadores pronósticos para la atenciónintegral al paciente con lupus eritematoso sistémico:Universidad de Ciencias Médicas de La Habana; 2011.

  12. Torricelli RM, Ulgolini-Lopes, Bonfa E. Antiphospholipid syndromedamage index (DIAPS): distinct long term kinetic inprimary antiphospholipid syndrome and antiphospholipidsyndrome related to systemic lupus erythematosus. Lupus2020; 29 (3): 256-62. doi: 10.1177/0961203320901598.

  13. Uludag O, Cene E, Gurel E, Cetin C, Bektas M, Yalcinkaya Y,et al. Description of damage in different clusters of patientswith antiphospholipid syndrome. Lupus 2022; 31 (4): 433-442. doi: 10.1177/09612033221079781..

  14. Riancho-Zarrabeitia L, Martinez-Taboada V, Rua-FigueroaI, Alonso F, Galindo-Izquierdo M, Ovalles J, et al. Antiphospholipidsyndrome (APS) in patients with systemic lupuserythematosus (SLE) implies a more severe disease withmore damage accrual and higher mortality. Lupus 2020; 29(12): 1556-65. doi: 10.1177/0961203320950477.

  15. Calcaterra I, Tufano A, Lupoli R, Iannuzzo G, Emmi G, DiMinno MND. Cardiovascular disease and antiphospholipidsyndrome: how to predict and how to treat? Pol Arch InternMed 2021; 131 (2): 161-70. doi: 10.20452/pamw.15415.

  16. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT,Jacobsen S, Kiss E, et al. Morbidity and mortality in theantiphospholipid syndrome during a 5-year period: a multicentreprospective study of 1000 patients. Annals of theRheumatic Diseases 2009; 68 (9): 1428-32. doi: 10.1136/ard.2008.093179.

  17. Kontic M, Stojanovich L, Mijailovic-Ivkovic M, Velinovic M,Srnka J, Zdravkovic M. Are the cutaneous manifestations inpatients with primary antiphospholipid syndrome a markerfor predicting lung manifestations? Clin Exp Rheumatol2018; 36 (1): 56-61.

  18. Pires da Rosa G EG, Cervera R. Non criteria manifestationsof antiphosfholipid syndrome: An overwiew. Span J Med2021; 1 (2). DOI: 10.24875/SJMED.21000003.

  19. Ruiz D, Oates JC , Kamen DL. Anti-phospholipid antibodiesand heart valve disease in systemic lupus erythematosus.Am J Med Sci 2018; 355 (3): 293-8. doi: 10.1016/j.amjms.2017.07.007.

  20. Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-GoddardG. Cardiac manifestations of antiphospholipid syndromewith focus on its primary form. Front Immunol 2019; 10:941. doi: 10.3389/fimmu.2019.00941.

  21. Ghembaza A, Saadoun D. Management of antiphospholipidsyndrome. Biomedicines 2020; 8 (508). doi: 10.3390/biomedicines8110508.

  22. Elbagir S, Elshafie AI, Elagib EM, Zickert A, Manivel VA,Pertsinidou E, et al. Associations with thrombosis arestronger for antiphosphatidylserine/prothrombin antibodiesthan for the Sydney criteria antiphospholipidantibody tests in SLE. Lupus 2021; 30 (8): 1289-99. doi:10.1177/09612033211014570.

  23. Liu T, Gu J, Wan L, Hu Q, Teng J, Liu H, et al. “Non-criteria”antiphospholipid antibodies add value to antiphospholipidsyndrome diagnoses in a large Chinese cohort. Arthr ResTher 2020; 22 (1). doi: 10.1186/s13075-020-2131-4.

  24. Belmar-Vega L, Fernandez-Fresnedo G, Irure-Ventura J,Orallo-Toural V, et al. Non-criteria antiphospholipid antibodies:risk factors for endothelial dysfunction in womenwith pre-eclampsia. Life (Basel) 2020; 10 (10): 241. doi:10.3390/life10100241.

  25. Meroni PL, Borghi MO. Antiphospholipid Antibody Assaysin 2021: Looking for a Predictive Value in Addition to aDiagnostic One. Front Immunol 2021;12: 726-820. doi:10.3389/fimmu.2021.726820.

  26. Kokuina E, Estévez del Toro M, Gutiérrez Rojas Á, OrtizLabrada A, Sánchez Bruzón Y, Pérez Campos D, et al.Anticuerpos antinucleosoma frente a marcadores inmunológicosconvencionales en el diagnóstico de la actividaddel lupus eritematoso sistémico. Rev Cubana Med 2014;53 (4): 430-44.

  27. Dall'Ara F, Reggia R, Taraborelli M, Andreoli L, Taglietti M,Frassi M, et al. Patients with longstanding primary antiphospholipidsyndrome: retrospective analysis of organdamage and mortality. Lupus 2014; 23 (12): 1255-8. doi:10.1177/0961203314534308.

  28. Tektonidou MG. Antiphospholipid syndrome nephropathy:from pathogenesis to treatment. Front Immunol 2018; 9:1181. doi: 10.3389/fimmu.2018.01181.

  29. De Azevedo FVA, Maia DG, de Carvalho JF, RodriguesCEM. Renal involvement in antiphospholipid syndrome.Rheumatol Int 2018; 38 (10): 1777-89. doi: 10.1007/s00296-018-4040-2.

  30. Gerhardsson J SB, Zickert A, Padyukov L, Svenungsson E,Gunnarsson I. Histological antiphospholipid-associatednephropathy versus lupus nephritis in patients with systemiclupus erythematosus: an observational cross-sectionalstudy with longitudinal follow-up. Arthritis Res Ther 2015;17 (1): 109. doi: 10.1186/s13075-015-0614-5.

  31. Cervera R, Serrano R, Pons-Estel GJ, Ceberio L, et al. Morbidityand mortality in the antiphospholipid syndrome duringa 10- year period: a multicentre prospective study of 1000patients. Ann Rheum Dis 2015; 74: 1011-8. doi: 10.1136/annrheumdis-2013-204838.

  32. Ahn SS, Jung SM, Yoo J, Lee SW, Song JJ, Park YB. Clinicalcharacteristics of patients with systemic lupus erythematosusshowing a false-positive result of syphilis screening.Rheumatol Int 2019; 39 (11): 1859-66. doi: 10.1007/s00296-019-04435-0.

  33. Svenungsson E, Antovic A. The antiphospholipid syndrome– often overlooked cause of vascular occlusions? J Int Med2020; 287 (4): 349-72. doi: 10.1111/joim.13022.

  34. Serrano R, Pons-Estel GJ, Espinosa G, Quintana RM, ReverterJC, Tassies D, et al. Long-term follow-up of antiphospholipidsyndrome: real-life experience from a single center. Lupus2020; 29 (9): 1050-9. doi: 10.1177/0961203320933009.

  35. Jatuworapruk K, Bhoopat L, Hanvivadhanakul P. Clinicaland immunological characteristics of antiphospholipidsyndrome in an Asian population: a retrospective study.Asian Pac J Allergy Immunol 2019; 37 (3): 171-8. doi:10.12932/AP-241217-0223.

  36. Knight JS, Kanthi Y. Mechanisms of immunothrombosis andvasculopathy in antiphospholipid syndrome. Semin Immunopathol2022; 1-16 doi: 10.1007/s00281-022-00916-w.

  37. Espinosa G, Cervera R. Antiphospholipid syndrome: frequency,main causes and risk factors of mortality. Nat Rev Rheumatology2010; 6 (5): 296-300. doi: 10.1038/nrrheum.2010.47.

  38. Garcia-Grimshaw M, Posadas-Pinto DR, Jimenez-Ruiz A,Valdes-Ferrer SI, Cadena-Fernandez A, Torres-Ruiz JJ, et al.Antiphospholipid syndrome-mediated acute cerebrovasculardiseases and long-term outcomes. Lupus 2022; 31 (2):228-37. doi: 10.1177/09612033221074178.

  39. Ricarte IF, Dutra LA, Abrantes FF, Toso FF, Barsottini OGP,Silva GS, et al. Neurologic manifestations of antiphospholipidsyndrome. Lupus 2018; 27 (9):1404-14. doi:10.1177/0961203318776110.

  40. Leal MBM, Romão V, Aguiar de Sousa D. Neurologic manifestationsof the antiphospholipid syndrome - an update.Curr Neurol Neurosci Rep 2021; 21 (8): 41. doi: 10.1007/s11910-021-01124-z.

  41. Djokovic A, Stojanovich L, Stanisavljevic N, Banicevic S,Smiljanic D, Milovanovic B. Relationship between cerebrovascularand valvular manifestations in a Serbiancohort of patients with antiphospholipid syndrome. ClinExp Rheumatol 2018; 36 (5): 850-5. doi: 10.1007/s11910-021-01124-z.

  42. García-Bello E, Torres de Taboada E. Manifestaciones hematológicasen pacientes adultos con lupus eritematososistémico. Rev Nac (Itauguá) 2019; 11 (1): 5-16.

  43. Ruiz-Irastorza G, Egurbide M-V, Ugalde J, Aguirre C. Highimpact of antiphospholipid syndrome on irreversible organdamage and survival of patients with systemic lupuserythematosus. Arch Inter Med 2004; 164 (1): 77-82. doi:10.1001/archinte.164.1.77.




2020     |     www.medigraphic.com